×

Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID

  • US 20040022787A1
  • Filed: 04/18/2003
  • Published: 02/05/2004
  • Est. Priority Date: 07/03/2000
  • Status: Abandoned Application
First Claim
Patent Images

1. A method for blocking B7 interactions with CTLA4 and/or CD28 comprising administering to a subject an effective amount of a first agent and a second agent, wherein a) the first agent is a soluble CTLA4 molecule, and b) the second agent is selected from a group consisting of immunosuppressive agents, corticosteroids, nonsteroidal antiinflammatory drugs, prednisone, azathioprine, methotrexate, TNFα

  • ;

    blockers or antagonists, infliximab, any biological agent targeting an inflammatory cytokine, hydroxychloroquine, sulphasalazopryine, gold salts, etanercept, anakinra, cyclophosphamide, leflunomide, collagen, dnaJ, a molecule that blocks TNF receptors, pegsunercept, a molecule that blocks cytokine function, AMG719, a molecule that blocks LFA-1 function, efalizumab, acetyl salicylic acid, choline magnesium salicylate, diflunisal, magnesium salicylate, salsalate, sodium salicylate, diclofenac, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, naproxen, nabumetone, phenylbutazone, piroxicam, sulindac, tolmetin, acetaminophen, ibuprofen, Cox-2 inhibitors, meloxicam, codeine phosphate, propoxyphene napsylate, oxycodone hydrochloride, oxycodone bitartrate and tramadol.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×